We next investigated whether the presence of CD24+ and CD24+CD271+ sub-populations led to enhanced overall survival of the CHL-1 cell line when treated with melanoma therapeutic compounds, by comparing to the A375M cell line which contains a CD271+ sub-population but does not contain CD24+ cells. The gene discussed is NGFR; the disease is melanoma.